Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound

Abstract

The object of the present invention is to find a new application of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof. Isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof is useful as a therapeutic agent for a disease involving a greatly elevated intraocular pressure.

1 . A prophylactic and/or therapeutic agent for a disease involving a greatly elevated intraocular pressure, comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof. 
     
     
         2 . The prophylactic and/or therapeutic agent according to  claim 1 , wherein
 the disease involving a greatly elevated intraocular pressure is acute primary angle closure, primary angle closure glaucoma, secondary angle closure glaucoma, or acute intraocular pressure elevation.   
     
     
         3 . The prophylactic and/or therapeutic agent according to  claim 1 , comprising 0.001 to 0.03% (w/v) of the isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or the salt thereof. 
     
     
         4 . The prophylactic and/or therapeutic agent according to  claim 1 , which does not comprise any other prophylactic and/or therapeutic agent for glaucoma or ocular hypertension than isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof. 
     
     
         5 . An eye drop, comprising the prophylactic and/or therapeutic agent according to  claim 1 . 
     
     
         6 . Isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof for the use of preventing and/or treating a disease involving a greatly elevated intraocular pressure. 
     
     
         7 . Isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof according to  claim 6 , wherein the disease involving a greatly elevated intraocular pressure is acute primary angle closure, primary angle closure glaucoma, secondary angle closure glaucoma, or acute intraocular pressure elevation. 
     
     
         8 . An eye drop, comprising isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof according to  claim 6 . 
     
     
         9 .- 13 . (canceled) 
     
     
         14 . A method for preventing and/or treating a disease involving a greatly elevated intraocular pressure, comprising administering isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof to patients with said disease which has to be prevented and/or treated. 
     
     
         15 . The method according to  claim 14 , wherein the disease involving a greatly elevated intraocular pressure is acute primary angle closure, primary angle closure glaucoma, secondary angle closure glaucoma, or acute intraocular pressure elevation. 
     
     
         16 . The method according to  claim 14 , wherein the administration amount of the isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or the salt thereof is 0.001 to 0.03% (w/v). 
     
     
         17 . The method according to  claim 14 , wherein any other prophylactic and/or therapeutic agent for glaucoma or ocular hypertension than isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof is not administered. 
     
     
         18 . The method according to  claim 14 , wherein the administration is instillation.